中国肿瘤临床
中國腫瘤臨床
중국종류림상
CHINESE JOURNAL OF CLINICAL ONCOLOGY
2013年
21期
1324-1327
,共4页
肺腺癌%培美曲塞%顺铂%近期疗效%安全性
肺腺癌%培美麯塞%順鉑%近期療效%安全性
폐선암%배미곡새%순박%근기료효%안전성
lung adenocarcinoma%pemetrexed%platinum recent therapeutic effect%safety profile
目的：观察培美曲塞联合顺铂一线治疗晚期肺腺癌的近期疗效和安全性。方法：经病理确诊为肺腺癌的41例初治（ⅢB～Ⅳ期）患者，采用培美曲塞联合顺铂全身化疗。每2个疗程进行疗效及安全性评价。结果：41例患者均可评价疗效，PR 17例，SD 20例，PD 4例。总的客观有效率（ORR）为41.5%，疾病控制率（DCR）90.3%。其中男性患者有效率显著高于女性患者（63.1%vs.22.7%，P=0.009）。所有患者的中位PFS为11.0个月，中位OS为12.6个月。6例伴脑转移患者经化疗同步全脑放疗后的颅内病灶得到较好控制，ORR为83.3%，DCR为100.0%。安全性方面，仅4.8%的患者出现了Ⅲ～Ⅳ度的中性粒细胞减少、恶心或呕吐。结论：培美曲塞联合顺铂一线治疗晚期肺腺癌患者疗效肯定，安全性良好。男性患者的有效率明显高于女性患者。对伴有脑转移的患者，化疗同时进行全脑放疗，疗效好且未额外增加不良反应。
目的：觀察培美麯塞聯閤順鉑一線治療晚期肺腺癌的近期療效和安全性。方法：經病理確診為肺腺癌的41例初治（ⅢB～Ⅳ期）患者，採用培美麯塞聯閤順鉑全身化療。每2箇療程進行療效及安全性評價。結果：41例患者均可評價療效，PR 17例，SD 20例，PD 4例。總的客觀有效率（ORR）為41.5%，疾病控製率（DCR）90.3%。其中男性患者有效率顯著高于女性患者（63.1%vs.22.7%，P=0.009）。所有患者的中位PFS為11.0箇月，中位OS為12.6箇月。6例伴腦轉移患者經化療同步全腦放療後的顱內病竈得到較好控製，ORR為83.3%，DCR為100.0%。安全性方麵，僅4.8%的患者齣現瞭Ⅲ～Ⅳ度的中性粒細胞減少、噁心或嘔吐。結論：培美麯塞聯閤順鉑一線治療晚期肺腺癌患者療效肯定，安全性良好。男性患者的有效率明顯高于女性患者。對伴有腦轉移的患者，化療同時進行全腦放療，療效好且未額外增加不良反應。
목적：관찰배미곡새연합순박일선치료만기폐선암적근기료효화안전성。방법：경병리학진위폐선암적41례초치（ⅢB～Ⅳ기）환자，채용배미곡새연합순박전신화료。매2개료정진행료효급안전성평개。결과：41례환자균가평개료효，PR 17례，SD 20례，PD 4례。총적객관유효솔（ORR）위41.5%，질병공제솔（DCR）90.3%。기중남성환자유효솔현저고우녀성환자（63.1%vs.22.7%，P=0.009）。소유환자적중위PFS위11.0개월，중위OS위12.6개월。6례반뇌전이환자경화료동보전뇌방료후적로내병조득도교호공제，ORR위83.3%，DCR위100.0%。안전성방면，부4.8%적환자출현료Ⅲ～Ⅳ도적중성립세포감소、악심혹구토。결론：배미곡새연합순박일선치료만기폐선암환자료효긍정，안전성량호。남성환자적유효솔명현고우녀성환자。대반유뇌전이적환자，화료동시진행전뇌방료，료효호차미액외증가불량반응。
Objective:The recent therapeutic effects and safety profile of pemetrexed plus cisplatin as first-line chemotherapy in advanced lung adenocarcinoma were evaluated. Methods:A total of 41 chemotherapy-naive locally advanced or metastatic non-small cell lung cancer patients, who were diagnosed with adenocarcinoma by pathological examination, were included. All patients received 500 mg/m2 pemetrexed on day 1. A total dose of 75 mg/m2 cisplatin was divided into three daily doses administered over 3 d. Treat-ments were repeated every three weeks. The therapeutic efficiency and safety profile were evaluated every two treatment cycles. Re-sults:All 41 patients were eligible for the evaluation of therapeutic efficiency. Seventeen patients showed partial response, 20 patients showed stable disease, and four patients showed disease progression. The overall response rate (ORR) was 41.5%and the disease con-trol rate (DCR) was 90.3%. Subgroup analysis showed that the ORR in males was significantly higher than that in females (63.1%vs. 22.7%, P=0.009). The median progression-free survival of all patients was 11.0 months, whereas the median overall survival was 12.6 months. The intracranial lesions of six patients with brain metastases were well controlled after chemotherapy and palliative whole brain radiotherapy. The ORR and DCR for these patients were 83.3%and 100.0%, respectively. In terms of safety, only 4.8%of the pa-tients showed gradesⅢandⅣneutropenia, nausea, or vomiting. Conclusion:Pemetrexed plus cisplatin is an effective and well-tolerat-ed regimen as first-line therapy for patients with lung adenocarcinoma. According to subgroup analysis, efficacy in males was signifi-cantly better than that in females. Good efficacy was observed in patients with brain metastases treated with chemotherapy and pallia-tive whole brain radiotherapy. No additional adverse effects were observed.
